GLORIA

GEOMAR Library Ocean Research Information Access

Sprache
Bevorzugter Suchindex
Ergebnisse pro Seite
Sortieren nach
Sortierung
Anzahl gespeicherter Suchen in der Suchhistorie
E-Mail-Adresse
Voreingestelltes Exportformat
Voreingestellte Zeichencodierung für Export
Anordnung der Filter
Maximale Anzahl angezeigter Filter
Autovervollständigung
Themen (Es wird nur nach Zeitschriften und Artikeln gesucht, die zu einem oder mehreren der ausgewählten Themen gehören)
Feed-Format
Anzahl der Ergebnisse pro Feed

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    In: Brain, Oxford University Press (OUP), Vol. 146, No. 1 ( 2023-01-05), p. 337-348
    Kurzfassung: Higher vascular disease burden increases the likelihood of developing dementia, including Alzheimer’s disease. Better understanding the association between vascular risk factors and Alzheimer’s disease pathology at the predementia stage is critical for developing effective strategies to delay cognitive decline. In this work, we estimated the impact of six vascular risk factors on the presence and severity of in vivo measured brain amyloid-beta (Aβ) plaques in participants from the population-based Rotterdam Study. Vascular risk factors (hypertension, hypercholesterolaemia, diabetes, obesity, physical inactivity and smoking) were assessed 13 (2004–2008) and 7 years (2009–2014) prior to 18F-florbetaben PET (2018–2021) in 635 dementia-free participants. Vascular risk factors were associated with binary amyloid PET status or continuous PET readouts (standard uptake value ratios, SUVrs) using logistic and linear regression models, respectively, adjusted for age, sex, education, APOE4 risk allele count and time between vascular risk and PET assessment. Participants’ mean age at time of amyloid PET was 69 years (range: 60–90), 325 (51.2%) were women and 190 (29.9%) carried at least one APOE4 risk allele. The adjusted prevalence estimates of an amyloid-positive PET status markedly increased with age [12.8% (95% CI 11.6; 14) in 60–69 years versus 35% (36; 40.8) in 80–89 years age groups] and APOE4 allele count [9.7% (8.8; 10.6) in non-carriers versus 38.4% (36; 40.8) to 60.4% (54; 66.8) in carriers of one or two risk allele(s)] . Diabetes 7 years prior to PET assessment was associated with a higher risk of a positive amyloid status [odds ratio (95% CI) = 3.68 (1.76; 7.61), P & lt; 0.001] and higher standard uptake value ratios, indicating more severe Aβ pathology [standardized beta = 0.40 (0.17; 0.64), P = 0.001]. Hypertension was associated with higher SUVr values in APOE4 carriers (mean SUVr difference of 0.09), but not in non-carriers (mean SUVr difference 0.02; P = 0.005). In contrast, hypercholesterolaemia was related to lower SUVr values in APOE4 carriers (mean SUVr difference −0.06), but not in non-carriers (mean SUVr difference 0.02). Obesity, physical inactivity and smoking were not related to amyloid PET measures. The current findings suggest a contribution of diabetes, hypertension and hypercholesterolaemia to the pathophysiology of Alzheimer’s disease in a general population of older non-demented adults. As these conditions respond well to lifestyle modification and drug treatment, further research should focus on the preventative effect of early risk management on the development of Alzheimer’s disease neuropathology.
    Materialart: Online-Ressource
    ISSN: 0006-8950 , 1460-2156
    RVK:
    Sprache: Englisch
    Verlag: Oxford University Press (OUP)
    Publikationsdatum: 2023
    ZDB Id: 1474117-9
    SSG: 12
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    In: Alzheimer's & Dementia, Wiley
    Kurzfassung: Reliable models to predict amyloid beta (Aβ) positivity in the general aging population are lacking but could become cost‐efficient tools to identify individuals at risk of developing Alzheimer's disease. METHODS We developed Aβ prediction models in the clinical Anti‐Amyloid Treatment in Asymptomatic Alzheimer's (A4) Study ( n  = 4,119) including a broad range of easily ascertainable predictors (demographics, cognition and daily functioning, health and lifestyle factors). Importantly, we determined the generalizability of our models in the population‐based Rotterdam Study ( n  = 500). RESULTS The best performing model in the A4 Study (area under the curve [AUC] = 0.73 [0.69–0.76] ), including age, apolipoprotein E ( APOE ) ε4 genotype, family history of dementia, and subjective and objective measures of cognition, walking duration and sleep behavior, was validated in the independent Rotterdam Study with higher accuracy (AUC = 0.85 [0.81–0.89]). Yet, the improvement relative to a model including only age and APOE ε4 was marginal. DISCUSSION Aβ prediction models including inexpensive and non‐invasive measures were successfully applied to a general population–derived sample more representative of typical older non‐demented adults.
    Materialart: Online-Ressource
    ISSN: 1552-5260 , 1552-5279
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2023
    ZDB Id: 2201940-6
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 3
    In: Alzheimer's & Dementia, Wiley, Vol. 18, No. S5 ( 2022-12)
    Kurzfassung: Alzheimer's disease and vascular brain injury are the most common causes of dementia, and are present jointly in 40% of individuals at time of death. Yet, the interaction between Alzheimer's and vascular pathology on cognition is largely undetermined. We studied the interaction between arteriosclerosis and plasma biomarkers of Alzheimer's disease on cognition in a general population without dementia. Method On stored plasma samples, obtained between 2002‐2005, we measured plasma levels of amyloid‐β 40 and amyloid‐β 42 by Simoa assay in 2252 participants of the population‐based Rotterdam Study (mean age: 68.9 years, 52% women). Arteriosclerosis was assessed using arterial calcification volumes that were quantified (semi‐)automatically on unenhanced computed tomography (CT). We captured the systemic burden of calcification, using a principal component analysis of calcification volumes in 4 different arterial vessel beds (intracranial and extracranial carotid arteries, coronary arteries and aortic arch). Cognitive assessment included the verbal fluency test, the letter‐digit substitution task, a 15‐word learning test, the Stroop test, and Purdue pegboard task. Global cognition (g‐factor) was calculated using a principal component analysis of these tests. We then determined the interaction between plasma amyloid‐β and calcification on cognitive performance, using multivariable linear regression models. Result Plasma levels of amyloid‐β and systemic arteriosclerosis were both associated with poorer cognitive performance. After mutual adjustment in multivariable models only calcification remained significantly associated (beta [95%CI] for g‐factor per 1‐SD increase in amyloid‐β 40 : ‐0.02 [‐0.07; 0.03]; amyloid‐β 42 : 0.03 [‐0.01; 0.08]; and calcification burden: ‐0.06 [‐0.09; ‐0.04] ). The association between amyloid‐β and cognition was stronger in individuals with higher burden of calcification (Figure 1), particularly for amyloid‐β 40 (interaction amyloid‐β 40 ×calcification: p = 0.04; amyloid‐β 42 ×calcification: p = 0.001). Results were broadly similar across cognitive tests. The observed interaction between amyloid‐β 40 and calcification volume was most profound for calcification burden in the intracranial carotid artery and aortic arch. Conclusion Arteriosclerosis and amyloid‐β display synergistic effects on cognition in the general population. This interaction was more profound for amyloid‐β 40 than for amyloid‐β 42 , suggesting our observations may relate particularly to amyloid angiopathy.
    Materialart: Online-Ressource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2022
    ZDB Id: 2201940-6
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 4
    In: Alzheimer's & Dementia, Wiley, Vol. 18, No. S11 ( 2022-12)
    Kurzfassung: Higher vascular risk increases the likelihood of developing dementia. Better understanding the association between vascular risk and Alzheimer’s disease (AD) pathology at the pre‐dementia stage is critical for developing effective strategies to delay cognitive decline. In this work, we estimated the impact of vascular risk on the presence and severity of in‐vivo measured brain beta‐amyloid (Aβ) plaques in participants from the population‐based Rotterdam Study. Method Vascular risk factors (hypertension, hypercholesterolemia, diabetes, obesity, physical inactivity, and smoking) were assessed twelve and seven years prior to 18 F‐florbetaben positron emission tomography (PET) in 506 dementia‐free participants. Vascualr risk factors were associated with binary amyloid PET status or continuous PET readouts (SUVr values) using logistic and linear regression models respectively, adjusted for age, sex, education, APOE4 risk allele count, and time between vascular risk and PET assessment Result Participants’ mean age at time of amyloid PET was 68 years (range: 60‐90), 262 (51.8%) were women and 158 (31.2%) carried at least one APOE4 risk allele (Figure 1). The adjusted prevalence estimates of an amyloid‐positive PET status markedly increased with age (12% in 60‐69y vs. 45.5% in 80‐89y age‐groups) and APOE4 allele count (8.3% in non‐carriers vs. 34.8 to 58.8% in carriers of one or two risk allele(s); Figure 2). A diagnosis of diabetes seven years prior to PET assessment was associated with a higher risk of a positive amyloid status (OR[95%CI] = 4.07[1.66‐9.71] , P = 0.002; Figure 3) and higher SUVr values, indicating more severe Aβ pathology (standardized beta = 0.478[0.205–0.750], P = 0.001; Figure 4). We found evidence for an association between hypertension and higher SUVr values in APOE4 carriers, but not in non‐carriers (interaction: standardized beta = 0.425[0.092–0.758] , P = 0.013; Figure 5). Hypercholesterolemia, obesity, physical inactivity and smoking were not related to amyloid PET measures. Conclusion The current findings suggest a contribution of diabetes and hypertension to the pathophysiology of AD. Since both conditions respond well to lifestyle modification and drug treatment, further research should be conducted to examine the preventative effect of early risk management on the development of AD neuropathology.
    Materialart: Online-Ressource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2022
    ZDB Id: 2201940-6
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 5
    In: Burns, Elsevier BV, Vol. 43, No. 3 ( 2017-05), p. 520-530
    Materialart: Online-Ressource
    ISSN: 0305-4179
    Sprache: Englisch
    Verlag: Elsevier BV
    Publikationsdatum: 2017
    ZDB Id: 2025040-X
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 6
    In: Alzheimer's & Dementia, Wiley, Vol. 18, No. S1 ( 2022-12)
    Kurzfassung: Higher vascular risk increases the likelihood of developing dementia. Better understanding the association between vascular risk and Alzheimer’s disease (AD) pathology at the pre‐dementia stage is critical for developing effective strategies to delay cognitive decline. In this work, we estimated the impact of vascular risk on the presence and severity of in‐vivo measured brain beta‐amyloid (Aβ) plaques in participants from the population‐based Rotterdam Study. Methods Vascular risk factors (hypertension, hypercholesterolemia, diabetes, obesity, physical inactivity, and smoking) were assessed twelve and seven years prior to 18 F‐florbetaben positron emission tomography (PET) in 506 dementia‐free participants. Vascualr risk factors were associated with binary amyloid PET status or continuous PET readouts (SUVr values) using logistic and linear regression models respectively, adjusted for age, sex, education, APOE4 risk allele count, and time between vascular risk and PET assessment. Results Participants’ mean age at time of amyloid PET was 68 years (range: 60‐90), 262 (51.8%) were women and 158 (31.2%) carried at least one APOE4 risk allele (Figure 1). The adjusted prevalence estimates of an amyloid‐positive PET status markedly increased with age (12% in 60‐69y vs. 45.5% in 80‐89y age‐groups) and APOE4 allele count (8.3% in non‐carriers vs. 34.8 to 58.8% in carriers of one or two risk allele(s); Figure 2). A diagnosis of diabetes seven years prior to PET assessment was associated with a higher risk of a positive amyloid status (OR[95%CI]=4.07[1.66–9.71] , P=0.002; Figure 3) and higher SUVr values, indicating more severe Aβ pathology (standardized beta=0.478[0.205–0.750], P=0.001; Figure 4). We found evidence for an association between hypertension and higher SUVr values in APOE4 carriers, but not in non‐carriers (interaction: standardized beta=0.425[0.092–0.758] , P=0.013; Figure 5). Hypercholesterolemia, obesity, physical inactivity and smoking were not related to amyloid PET measures. Conclusion The current findings suggest a contribution of diabetes and hypertension to the pathophysiology of AD. Since both conditions respond well to lifestyle modification and drug treatment, further research should be conducted to examine the preventative effect of early risk management on the development of AD neuropathology.
    Materialart: Online-Ressource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2022
    ZDB Id: 2201940-6
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 7
    In: Alzheimer's & Dementia, Wiley, Vol. 13, No. 7S_Part_22 ( 2017-07)
    Materialart: Online-Ressource
    ISSN: 1552-5260 , 1552-5279
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2017
    ZDB Id: 2201940-6
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 8
    In: GeroScience, Springer Science and Business Media LLC
    Kurzfassung: Neurofilament light chain (NfL) is a promising biomarker for risk stratification and disease monitoring of dementia, but its utility in the preclinical disease stage remains uncertain. We determined the association of plasma NfL with (change in) neuroimaging markers and cognition in the population-based Rotterdam Study, using linear and logistic regression and mixed-effects models. Plasma NfL levels were measured using the Simoa NF-light™ assay in 4705 dementia-free participants (mean age 71.9 years, 57% women), who underwent cognitive assessment and brain MRI with repeated assessments over a 10-year follow-up period. Higher plasma NfL was associated with worse cognitive performance at baseline (g-factor: β  =  − 0.12 (− 0.15; − 0.09), p   〈  0.001), and accelerated cognitive decline during follow-up on the Stroop color naming task ( β  = 0.04 (0.02; 0.06), p   〈  0.001), with a smaller trend for decline in global cognition (g-factor β  =  − 0.02 (− 0.04; 0.00), p  = 0.044). In the subset of 975 participants with brain MRI, higher NfL was associated with poorer baseline white matter integrity (e.g., global mean diffusivity: β  = 0.12 (0.06; 0.19), p   〈  0.001), with similar trends for volume of white matter hyperintensities ( β  = 0.09 (0.02; 0.16), p  = 0.011) and presence of lacunes (OR = 1.55 (1.13; 2.14), p  = 0.007). Plasma NfL was not associated with volumes or thickness of the total gray matter, hippocampus, or Alzheimer signature regions. In conclusion, higher plasma NfL levels are associated with cognitive decline and larger burden of primarily white matter pathology in the general population.
    Materialart: Online-Ressource
    ISSN: 2509-2723
    Sprache: Englisch
    Verlag: Springer Science and Business Media LLC
    Publikationsdatum: 2023
    ZDB Id: 2886418-9
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 9
    In: Neurobiology of Aging, Elsevier BV, Vol. 106 ( 2021-10), p. 197-206
    Materialart: Online-Ressource
    ISSN: 0197-4580
    Sprache: Englisch
    Verlag: Elsevier BV
    Publikationsdatum: 2021
    ZDB Id: 1498414-3
    SSG: 12
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 10
    In: Alzheimer's & Dementia, Wiley, Vol. 17, No. S5 ( 2021-12)
    Kurzfassung: Neurofilament light chain (NfL) is known as a promising biomarker for risk stratification and disease monitoring of dementia due to Alzheimer’s disease, but the underlying pathophysiological substrates remain largely elusive. Moreover, it is uncertain whether NfL levels are able to capture changes in cognitive performance prior to the onset of clinical cognitive decline. We studied the relation of plasma NfL with cognition and structural brain imaging markers in a general population without dementia. Method Plasma level of NfL was measured using the Simoa NF‐light™ assay in 4,207 dementia‐free participants of the population‐based Rotterdam Study cohort (mean age 71.6 years, 57% women). Participants underwent repeated cognitive assessment, and a subset of 970 had brain MRI. We used linear and logistic regression (cross‐sectional) and mixed‐effects models (longitudinal) to determine the association of plasma NfL with (changes in) cognition and brain tissue volumetry, white matter integrity and markers of cerebral small‐vessel disease (lacunes, white matter hyperintensities and microbleeds). Result At baseline, higher plasma NfL level was significantly associated with a worse cognitive performance (g‐factor: β=‐0.06 95%CI ‐0.12;0), and more specifically with lower test scores on the Stroop 3 test (β=‐0.07 95%CI ‐0.12;‐0.01), and Perdue Pegboard (β=‐0.12 95%CI ‐0.18;‐0.06). Similarly, among 2,850 participants with repeated cognitive assessment, baseline NfL level was significantly associated with a stronger decline in cognition (g‐factor (β=‐0.02 95%CI ‐0.04;0), driven by faster decline on Stroop 1 & 2 tests (β=‐0.03 95% ‐0.04;‐0.01, β=‐0.03 95%CI ‐0.05;‐0.02, Figure 1). In participants with brain MRI, NfL level was significantly associated at baseline with larger volumes of white matter hyperintensities (β= 0.12 95%CI 0.04;0.20), more lacunar infarcts (OR= 1.69 95%CI 1.20;2.39), and worse fractional anisotropy (β=‐0.10 95%CI ‐0.18;‐0.02) and mean diffusivity (β=0.09 95%CI 0.02;0.16), but not with grey matter volumes. Plasma NfL level was not significantly related to progression of structural brain changes over time (n=738). Conclusion In this large community‐dwelling population, higher plasma NfL levels are associated with accelerated cognitive decline and larger burden of white matter pathology. These findings suggest NfL as a predominant biomarker of axonal rather than neuronal damage in monitoring of disease progression and treatment effects.
    Materialart: Online-Ressource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2021
    ZDB Id: 2201940-6
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...